Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Erenumab (erenumab-aooe in the US) effectively reduces monthly migraine days in episodic and chronic migraine. This traditional outcome does not capture the intensity of headache pain on days with migraine.
Methods: This post hoc analysis of two pivotal randomized, placebo-controlled studies in patients with episodic migraine and chronic migraine examined the effect of erenumab 70 and 140 mg on migraine pain. Cumulative monthly migraine pain intensity is the sum of the peak pain intensity scores (0 = no migraine to 3 = migraine day with severe pain) on migraine days. Change from baseline in cumulative monthly migraine pain and average monthly pain intensity was assessed over months 4 to 6 for episodic migraine and month 3 for chronic migraine; change in average monthly pain intensity was assessed among monthly migraine days responders/non-responders.
Results: Efficacy analysis included 946 patients for the episodic migraine study and 656 patients for the chronic migraine study. Cumulative monthly migraine pain decreased significantly with erenumab versus placebo ( < 0.001, for episodic migraine and chronic migraine). In addition, monthly average migraine pain intensity decreased significantly with erenumab versus placebo for episodic migraine ( < 0.01); decreases were non-significant for chronic migraine. In comparison with placebo-treated patients, a greater proportion of erenumab-treated patients were pain intensity responders regardless of threshold used. Episodic migraine and chronic migraine patients with a ≥50% reduction in monthly migraine days (responders) had a greater reduction in monthly average pain intensity than non-responders.
Conclusions: Erenumab reduced cumulative monthly migraine pain in episodic migraine and chronic migraine patients and significantly reduced monthly average migraine pain in episodic migraine, demonstrating treatment benefit beyond reduction in migraine frequency. ClinicalTrials.gov, NCT02456740; ClinicalTrials.gov, NCT02066415.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/03331024211028966 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Randomized Trial of Cervical Stabilization Exercise Training Via Telerehabilitation for Migraine.
Pain Manag Nurs
September 2025
Ankara Yıldırım Beyazıt University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey.
Purpose: To compare the effects of cervical stabilization exercise training via telerehabilitation (CSET-T) in addition to standard treatment on pain, forward head posture, cervical mobility, muscle performance, functional status, sleep quality, and quality of life in individuals with migraine in comparison to the standard treatment alone.
Methods: The control group (n = 20) received standard treatment alone (medication+recommendations). The stabilization group (n = 20) was given CSET-T in addition to standard treatment 3 days a week for 8 weeks.
Headache in optic neuritis: A retrospective case-control study revealing clinical and radiological associations of an underrecognized symptom.
Mult Scler Relat Disord
September 2025
Neurologist-Neuroimmunologist. Associate Professor of Neurology, Neuroscience Department, Division of Neurology, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia. Electronic address:
Background: Headache is a common but underrecognized symptom in optic neuritis (ON), with potential implications for diagnosis and management.
Objective: To assess the clinical and radiological factors associated with headache in patients with acute ON.
Methods: We conducted a retrospective case-control study in a tertiary hospital in Bogotá, Colombia (2022-2024).
Investigation of Sensory and Neuropsychological Parameters in Migraine Sufferers: A Cross-Sectional Study with Negative Findings.
Neurol Ther
September 2025
Department of Neurology, Neurocritical Care, and Neurorehabilitation, Christian Doppler University Hospital, Centre for Cognitive Neuroscience, Paracelsus Medical University, Member of ERN EpiCARE, 5020, Salzburg, Austria.
Introduction: Migraine headache not only is associated with high levels of suffering but also represents a considerable socioeconomic challenge. It is linked to various psychological and physiological impairments, including sensorimotor and somatosensory dysfunction, like those observed in other persistent pain syndromes. This study aims to determine whether individuals with high-frequency episodic (HFEM) or chronic migraine (CM) exhibit differences in somatosensory perception compared to healthy individuals and to explore potential correlations with neuropsychological features.
View Article and Find Full Text PDFNo Increase in Blood Pressure Assessed With the 24-h Holter Monitoring in Patients With Episodic Migraine During Early Treatment With Anti-CGRP Monoclonal Antibodies: A Prospective Observational Study (SAFHYPER).
Eur J Neurol
September 2025
Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy.
Background: Migraine is associated with an increased cardiovascular risk, including hypertension. Anti-calcitonin gene related peptide (CGRP) monoclonal antibodies (mAbs) are effective preventive treatments, but concerns have been raised about their potential hypertensive effects. Herein, we assess the early changes in blood pressure (BP) during anti-CGRP mAbs treatment in patients with migraine using 24-h Holter monitoring.
View Article and Find Full Text PDFExploring the Association of Migraine Susceptibility SNPs With the Risk of Chronic Migraine.
Eur J Pain
October 2025
Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia, Italy.
Background: Although robust genetic markers for episodic migraine (EM) have been identified, variants associated with chronic migraine (CM) are still unknown. Given the potential pathophysiologic overlap between EM and CM, we investigated whether six single nucleotide polymorphisms (SNPs), robustly associated with EM susceptibility (LRP1 rs11172113, PRDM16 rs10797381, FHL5 rs7775721, TRPM8 rs10166942, near TSPAN2 rs2078371 and MEF2D rs1925950) also play a role in the risk of developing CM.
Methods: A total of 200 EM and 202 CM participants were prospectively included.